FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Infusion Options RITUXAN 728 MG QS 728 mL 0 Recall

RITUXAN 728 MG QS 728 mL 0

Infusion Options, Inc. · Brooklyn, NY

Risk level
Class II
Reported by FDA
Aug 21, 2019
Recall ID
D-1809-2019
Check your lot numberHow we source this data

Summary

Infusion Options recalled RITUXAN 728 MG QS 728 mL 0 starting Jun 12, 2019. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1809-2019 on Aug 21, 2019. Reason: Lack of Assurance of Sterility. Status: Terminated.

Why it was recalled

Lack of Assurance of Sterility

Product description

RITUXAN 728 MG QS 728 mL 0.9% NACL IVPB; RITUXAN 560 MG / 306 ml 0.9% NACL; RITUXAN 562 MG IN 562 ml 0.9% NACL; RITUXAN 700 MG QS 700 mL 0.9% NACL IVPB; RITUXAN 1000 MG / 350 mL 0.9% NACL IVPB RITUXAN 730 MG / 730 mL 0.9% NACL IVPB; RITUXAN 1000 MG QS 1000 ml NS; RITUXAN 1000 MG QS 200 ml 0.9% NACL; RITUXAN 500 MG / 300 ml 0.9% NACL; RITUXAN 660 MG QS 660 ml 0.9% NACL; RITUXAN 770 MG QS 770 mL 0.9% NACL IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233

Lot numbers, UPCs & expiration codes

All lots within expiry

Where it was sold

NY only

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1809-2019
Classification
Class II
Status
Terminated
Recall initiated
Jun 12, 2019
FDA report date
Aug 21, 2019
Quantity
N/A
Recall type
Voluntary: Firm initiated
Recalling firm
Infusion Options, Inc.

Original FDA data

Every field from FDA enforcement report D-1809-2019, exactly as published.

Show all FDA fields
City
Brooklyn
State
NY
Status
Terminated
Country
United States
Event ID
83136
Address
5924 13th Ave
Code information
All lots within expiry
Postal code
11219-4934
Report date
Aug 21, 2019
Product type
Drugs
Recall number
D-1809-2019
Classification
Class II
Recalling firm
Infusion Options, Inc.
Termination date
Mar 21, 2025
Reason for recall
Lack of Assurance of Sterility
Voluntary / mandated
Voluntary: Firm initiated
Product description
RITUXAN 728 MG QS 728 mL 0.9% NACL IVPB; RITUXAN 560 MG / 306 ml 0.9% NACL; RITUXAN 562 MG IN 562 ml 0.9% NACL; RITUXAN 700 MG QS 700 mL 0.9% NACL IVPB; RITUXAN 1000 MG / 350 mL 0.9% NACL IVPB RITUXAN 730 MG / 730 mL 0.9% NACL IVPB; RITUXAN 1000 MG QS 1000 ml NS; RITUXAN 1000 MG QS 200 ml 0.9% NACL; RITUXAN 500 MG / 300 ml 0.9% NACL; RITUXAN 660 MG QS 660 ml 0.9% NACL; RITUXAN 770 MG QS 770 mL 0.9% NACL IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
Distribution pattern
NY only
Recall initiation date
Jun 12, 2019
Initial firm notification
Letter
Center classification date
Aug 15, 2019

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1809-2019, published Aug 21, 2019. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls